A geometric mean ratio of approximately 1.0 — sitting squarely inside the 0.80–1.25 bioequivalence boundary — is about as clean a pharmacokinetic result as a Phase 3 trial can produce, and that precision matters enormously for what TG Therapeutics is trying to accomplish with ublituximab in a crowded anti-CD20 field.
The ENHANCE trial enrolled RMS patients into a straightforward two-arm design: the approved split initiation of 150 mg on Day 1 and 450 mg on Day 15 versus a consolidated 600 mg single infusion on Day 1 with a placebo infusion at Day 15. Total cumulative dose through Day 15 was identical across arms, which was the design’s key structural move — it isolated timing as the only variable. AUC through Week 16 was the primary endpoint, and the GMR landing at ~1.0 eliminates any meaningful pharmacokinetic argument against the consolidated regimen. Secondary endpoints reinforced the picture: B-cell depletion was comparable, MRI outcomes tracked with prior ULTIMATE I and II data, and infusion-related reactions were actually lower than historical rates from the approval studies, with zero Grade 3 or higher events in either arm.
The clinical significance here runs deeper than scheduling convenience. Infusion-center burden is a real access barrier in RMS — a disease where treatment interruptions correlate with relapse risk. Eliminating a mandated Day 15 visit removes a discrete failure point between prescription and full initiation. If the supplemental BLA lands with FDA in the second half of 2026 and earns approval, ublituximab becomes the only IV anti-CD20 in RMS where therapy can begin and complete initiation dosing in a single encounter. Ocrelizumab’s original IV formulation requires two infusions two weeks apart, and ofatumumab is subcutaneous with its own multi-dose loading sequence. Among single-visit options, the subcutaneous ocrelizumab formulation, Ocrevus Zunovo, also initiates in one injection, though it is not an IV therapy.
The regulatory filing is the next inflection point, but the data quality here does not leave much room for a bioequivalence dispute. What actually determines whether this label update moves the commercial needle is real-world uptake data post-approval — specifically whether infusion centers in high-volume MS practices shift new-patient starts toward ublituximab once a single-visit initiation is on the label.
Correction (June 2, 2026): An earlier version stated that no competitor offered a comparable single-visit initiation pathway. Ocrevus Zunovo, a subcutaneous ocrelizumab formulation, also completes initiation in a single visit; ublituximab’s distinction is as the only IV anti-CD20 with single-encounter initiation. The paragraph has been updated.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
